Innovations in The Management of Diabetes: Next generation treatments and market dynamics

Table of Contents

Executive Summary

• Introduction
• Currently marketed innovatives
• Future drivers of growth and innovation
• Key companies and pipelines
• Future trends and implications

Chapter 1 Introduction

• Summary
• Introduction
• Disease description
• Type 1 diabetes
• Type 2 diabetes
• An increasing global health concern
• Increasing patient population
• Underdiagnosed and undertreated
• Economic burden

Chapter 2 Currently marketed innovatives

• Summary
• Introduction
• Current growth drivers
• Insulins
  • Leading marketed innovatives within insulin
  • Exubera
• Oral anti-diabetics (OADs)
  • Leading marketed innovatives in OADs
• Other diabetic drugs
  • Leading marketed innovatives in other diabetic drugs

Chapter 3 Future drivers of growth and innovation

• Summary
• Introduction
• Unmet need
• Key events in the global diabetes market
• ACCORD trial halted 18 months early
• Inhaled insulins fail to impact market
• FDA considers stricter rules for diabetes drugs
• Toward the prevention and further treatment of diabetes
• Non-invasive forms of insulin via new drug delivery technologies
• Inhaled insulins
  • Future potential of inhaled insulins
• Oral insulins
  • Future potential of oral insulins
• Insulin patches
  • Future potential of insulin patches
• Emerging new drug classes: targeting underlying causes
• Incretin mimetics: GLP-1 agonists and DDP-IV inhibitors
  • GLP-1 agonists in development
  • Novel GLP-1 agonists addressing unmet need
  • DDP-IV inhibitors in development
  • Novel DDP-IV inhibitors addressing unmet need
• PPAR agonists
  • PPAR agonists in development
  • Novel PPAR agonists addressing unmet need
• Sodium glucose co-transporter (SGLT) inhibitors
  • SGLT inhibitors in development
• Cannabinoid-1 (CB1) receptor antagonists
  • CB-1 receptor antagonists in development
• Glucokinase activators (GKA)
  • Glucokinase activators in development
• Other novel drugs in development
  • Protein tyrosine phosphatase 1B (PT1B) inhibitors
  • Glycogen synthase kinase-3 (GSK-3) inhibitors
  • 11-beta-hydroxysteroid dehydrogenase (11beta-HSD1) inhibitors
  • GPR119 agonists
• Cell transplantation and innovative therapies

Chapter 4 Key companies and pipelines

• Summary
• Introduction
• Leading competitive strategies
• Lifecycle management
• Diversification
• Franchise development
• New market entry
• Leading players
• Novo Nordisk
  • Currently marketed innovatives profile
  • R&D/innovatives profile
• Takeda
  • Currently marketed innovatives profile
  • R&D/innovatives profile
• Sanofi-Aventis
  • Currently marketed innovatives profile
  • R&D/innovatives profile
• GSK
  • Currently marketed innovatives profile
  • R&D/innovatives profile
• Lilly
  • Currently marketed innovatives profile
  • R&D/innovatives profile
• Merck.
  • Currently marketed innovatives profile
  • R&D/innovatives profile

Chapter 5 Future trends and implications

• Summary
• Introduction
• Future market growth
• Competitive strategy and future potential

Chapter 6 Appendix

• IMS data
• Index

List of Figures

• Figure 3.1: Unmet needs in diabetes, 2008
• Figure 3.2: Innovative diabetes pipeline, 2007
• Figure 3.3: Addressing unmet need of novel GLP-1 agonists versus insulin
• Figure 3.4: Addressing unmet need of novel DDP-IV inhibitors versus TZDs
• Figure 3.5: Addressing unmet need of novel PPAR agonists* versus TZDs
• Figure 4.6: Competitive dynamics of the leading players in the diabetes market, 2007
• Figure 5.7: Drivers and resistors of growth in the innovative diabetes market, 2007
• Figure 5.8: Forecast sales growth for the global diabetes market, 2007-12
• Figure 5.9: Outlook for leading pharmaceutical companies in the innovative diabetes market

List of Tables

• Table 2.1: Breakdown of the global diabetes market by drug class, 2003-07
• Table 4.2: Leading diabetes companies*, 2006-07
• Table 4.3: Novo Nordisk' s currently marketed innovative diabetes profile, 2003-07
• Table 4.4: Novo Nordisk' s diabetes R&D/innovatives profile
• Table 4.5: Takeda' s currently marketed innovative diabetes profile, 2003-07
• Table 4.6: Takeda' s diabetes R&D/innovatives profile
• Table 4.7: Sanofi-Aventis' currently marketed innovative diabetes profile, 2003-07
• Table 4.8: Sanofi-Aventis' diabetes R&D/innovatives profile
• Table 4.9: GSK' s currently marketed innovative diabetes profile, 2003-07
• Table 4.10: GSK' s diabetes R&D/innovatives profile
• Table 4.11: Lilly' s currently marketed diabetes innovative diabetes, 2003-07
• Table 4.12: Lilly' s diabetes R&D/innovatives profile
• Table 4.13: Merck' s currently marketed innovative diabetes profile, 2003-07
• Table 4.14: Merck' s diabetes R&D/innovatives profile